|
gptkbp:instanceOf
|
gptkb:drug
proton pump inhibitor
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A02BC06
|
|
gptkbp:brand
|
gptkb:Dexilant
gptkb:Kapidex
|
|
gptkbp:CASNumber
|
138530-94-6
|
|
gptkbp:chirality
|
R-enantiomer of lansoprazole
|
|
gptkbp:developedBy
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:drugClass
|
proton pump inhibitor
|
|
gptkbp:eliminationHalfLife
|
1-2 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C16H14F3N3O2S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dexlansoprazole
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits H+/K+ ATPase in gastric parietal cells
|
|
gptkbp:metabolism
|
liver (CYP2C19, CYP3A4)
|
|
gptkbp:pregnancyCategory
|
C (US)
B1 (Australia)
|
|
gptkbp:relatedTo
|
gptkb:lansoprazole
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
flatulence
|
|
gptkbp:usedFor
|
gptkb:erosive_esophagitis
gptkb:gastroesophageal_reflux_disease
|
|
gptkbp:bfsParent
|
gptkb:proton_pump_inhibitors
gptkb:Nexium
gptkb:Dexilant
gptkb:Kapidex
|
|
gptkbp:bfsLayer
|
7
|